Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): a multi-cohort adaptive phase I clinical trial.

A Vanbinst

Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): a multi-cohort adaptive phase I clinical trial.

Research output: Unpublished contribution to conference › Poster

Original language	English
Publication status	Published - 2021
Event	ESMO CONGRES - Duration: 16 Sep 2021 → 21 Sep 2021

Conference

Conference	ESMO CONGRES
Period	16/09/21 → 21/09/21

Cite this

@conference{1f9a9737933d45b691654169029b6f08,

title = "Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): a multi-cohort adaptive phase I clinical trial.",

author = "A Vanbinst",

year = "2021",

language = "English",

note = "ESMO CONGRES ; Conference date: 16-09-2021 Through 21-09-2021",

}